Kyverna Therapeutics (KYTX) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
SAB Biotherapeutics (SABS) has outperformed Kyverna Therapeutics (KYTX) over the past year, losing 28.9% versus a loss of 39.9%. Kyverna Therapeutics is the larger company by market cap ($269.3 million vs $253.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYTX | SABS |
|---|---|---|
| Share price | $4.26 | $2.81 |
| Market cap | $269.33M | $253.15M |
| 1-day change | -2.52% | -3.44% |
| YTD return | -54.68% | -24.87% |
| 1-year return | -39.92% | -28.86% |
| 5-year return | — | -97.32% |
| EPS (TTM) | $-2.75 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-161.31M | $13.27M |
| 52-week high | $13.67 | $5.15 |
| 52-week low | $4.18 | $2.44 |
| Distance from 52-week high | -68.84% | -45.44% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +613.62% | +314.23% |
| Average volume | 867.28K | 633.60K |
| Shares outstanding | 63.22M | 90.09M |
| Employees | 172 | 86 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SABS has outperformed KYTX by 11.1 percentage points over the past year.
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 172 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees
KYTX vs SABS FAQ
Which is bigger, Kyverna Therapeutics or SAB Biotherapeutics?
Kyverna Therapeutics (KYTX) is larger, with a market capitalization of $269.33M compared with $253.15M for SAB Biotherapeutics (SABS).
Which stock has performed better over the past year, KYTX or SABS?
SABS returned -28.86% over the past 12 months, compared with -39.92% for KYTX (price return, excluding dividends). Past performance does not predict future results.
Are Kyverna Therapeutics and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.